

Listing of Claims:

1. (Currently Amended) A method of assessing whether a patient is afflicted with ovarian carcinoma, the method comprising a) determining the amount of a SEQ ID NO:1 marker in a patient ovarian tissue sample, ~~wherein the marker is selected from Table 4;~~ b) determining the normal amount of the SEQ ID NO:1 marker in a control non-cancerous ovarian tissue sample; and c) comparing the amounts of the marker between the patient ovarian tissue sample and the control non-cancerous ovarian tissue sample, wherein a significant increase in the amount of the marker in the patient sample from the normal level is an indication that the patient is afflicted with ovarian carcinoma.

Claims 2-3 (Canceled).

4. (Original) The method of claim 1 wherein the amount of the marker is determined in the patient sample and the non cancerous sample by hybridizing a polynucleotide expressed by the marker with an oligonucleotide or polynucleotide that is complementary to the polynucleotide expressed by the marker.

5. (Original) The method of claim 1 wherein the determination of the amount of the marker comprises performing a polymerase chain reaction.

6. (Original) The method of claim 1 wherein the determination of the amount of the marker comprises performing quantitative real-time reverse transcription-polymerase chain reaction.

7. (Original) The method of claim 1 wherein the determination of the amount of the marker comprises the use of a microarray.

Claims 8-20 (Canceled).

7. (Original) The method of claim 1 wherein the determination of the amount of the marker comprises the use of a microarray.

Claims 8-20 (Canceled).